FDA Completes Human Dura Mater Classification, Undeterred By CJD Threat
This article was originally published in The Gray Sheet
Executive Summary
FDA will classify human dura mater as a Class II device (with special controls), despite lingering concerns raised by cases of dura mater-transmitted Creutzfeldt Jakob Disease (CJD) abroad
You may also be interested in...
Tissue Registration & Listing Reg Draws Attention To Unissued FDA Rules
FDA is implementing new tissue bank registration and listing requirements, though the two remaining parts of the tripartite tissue regulatory framework have yet to be finalized
Tissue Registration & Listing Reg Draws Attention To Unissued FDA Rules
FDA is implementing new tissue bank registration and listing requirements, though the two remaining parts of the tripartite tissue regulatory framework have yet to be finalized
FDA Reasserts Dura Mater Device Status During Interim Preceding GTPs
FDA is moving forward with rules establishing human dura mater as a Class II medical device before the agency issues guidelines transitioning the product into the purview of tissue regulation